author-photo

Bella Kaufman

Sheba Medical Center
Tel Aviv University

243

Papers

17639

Citations

Citation Trend

Filter By

Papers (243) Sort By

Journal Conference Others

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.

2021 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (33)
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

2021 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (61)
Abstract PS11-03: Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: A subgroup analysis of germline BRCA1 or BRCA2 mutations from the phase 3 BROCADE3 trial

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Immune checkpoint inhibitors-related encephalitis in melanoma and non-melanoma cancer patients: a single center experience

2021 Supportive Care in Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Adjuvant T-DM1 versus Trastuzumab in Patients with Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer: Subgroup Analyses from KATHERINE.

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial.

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial.

2021 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover).

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)